Ikarian Capital’s Cogent Biosciences COGT Stock Holding History

Ikarian Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.3M	Buy	+370,084	New	+$12.9M	1.54%	17
2025 Q4	–	Sell	-11,280	Closed	-$162K	–	191
2025 Q3	$162K	Sell	11,280 -1,024,248	-99%	-$12.1M	0.02%	155
2025 Q2	$7.44M	Buy	+1,035,528	New	+$5.74M	1.43%	26
2023 Q4	–	Sell	-62,766	Closed	-$612K	–	147
2023 Q3	$612K	Hold	62,766	–	–	0.07%	109
2023 Q2	$743K	Hold	62,766	–	–	0.12%	91
2023 Q1	$677K	Hold	62,766	–	–	0.15%	89
2022 Q4	$726K	Sell	62,766 -100,000	-61%	-$1.24M	0.18%	53
2022 Q3	$2.43M	Sell	162,766 -87,234	-35%	-$1.2M	0.48%	54
2022 Q2	$2.26M	Buy	+250,000	New	+$1.71M	0.41%	55
2021 Q4	–	Sell	-30,727	Closed	-$258K	–	202
2021 Q3	$258K	Sell	30,727 -11,035	-26%	-$84.6K	0.02%	200
2021 Q2	$338K	Hold	41,762	–	–	0.03%	198
2021 Q1	$367K	Hold	41,762	–	–	0.01%	263
2020 Q4	$469K	Buy	+41,762	New	+$459K	0.02%	192

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ikarian Capital's COGT Position: Q2 2026 in Review

Ikarian Capital opened a new position in Cogent Biosciences (COGT) in Q2 2026: 370,084 shares worth $14.3M. The stake represents 1.54% of the portfolio and ranks #17 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in COGT as recently as Q3 2025.

Ikarian Capital first reported a position in COGT in Q4 2020 and has held it in 13 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Ikarian Capital held 370,084 shares of Cogent Biosciences worth $14.3M as of Q2 2026.
Cogent Biosciences was a new Ikarian Capital position in Q2 2026.
Cogent Biosciences made up 1.54% of Ikarian Capital's portfolio in Q2 2026, its #17 holding.
Ikarian Capital first reported a position in Cogent Biosciences in Q4 2020 and has held it in 13 quarters since.
323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.